Drugs for Contractures, Pterygia, and Spondylocarpotarsal Fusion Syndrome 1a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 332)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Methylphenidate |
Approved, Investigational |
Phase 4 |
|
113-45-1 |
4158 |
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
298-59-9 (hydrochloride)
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
4311/B Ciba
AC1L1HJM
alpha-Phenyl-2-piperidineacetate methyl ester
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
a-Phenyl-2-piperidineacetate methyl ester
a-Phenyl-2-piperidineacetic acid methyl ester
C 4311
C07196
Calocain
Celltech brand OF methylphenidate hydrochloride
Centedein
Centedrin
Centedrine
Centredin
Cephalon brand OF methylphenidate hydrochloride
CHEBI:6887
CHEMBL796
CID4158
Concerta
D04999
Daytrana
Daytrana (TN)
DB00422
DB06701
DEA No. 1724
d-methylphenidate HCl
D-Methylphenidate HCL
EINECS 204-028-6
Equasym
Focalin
Focalin XR
HSDB 3126
Hydrochloride, methylphenidate
L001307
LS-565
Mallinckrodt brand OF methylphenidate hydrochloride
Meridil
Metadate
Metadate CD
Metadate ER
Methyl (2-phenyl-2-(2-piperidyl)acetate)
methyl 2-phenyl-2-piperidin-2-ylacetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetic acid
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl alpha-phenyl-alpha-2-piperidinylacetic acid
Methyl a-phenyl-a-(2-piperidyl)acetate
Methyl a-phenyl-a-(2-piperidyl)acetic acid
Methyl a-phenyl-a-2-piperidinylacetate
Methyl a-phenyl-a-2-piperidinylacetic acid
Methyl phenidate
|
Methyl phenidyl acetate
Methyl phenidylacetate
Methyl phenidylacetic acid
methyl phenyl(piperidin-2-yl)acetate
methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetic acid
methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetic acid
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
methylphenidate
Methylphenidate
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
Methylphenidate (USAN/INN)
Methylphenidate [INN:BAN]
Methylphenidate HCl
Methylphenidate HCL
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidic acid
Methylphenidylacetate hydrochloride
Methypatch
MethyPatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
MPH
nchembio.2007.55-comp28
NCI-C56280
Novartis brand 1 OF methylphenidate hydrochloride
Novartis brand 2 OF methylphenidate hydrochloride
Phenidylate
Plimasine
PMS-Methylphenidate
Riphenidate
Ritalin
Ritalin hydrochloride
Ritalin LA
Ritalin SR
Ritaline
Ritalin-SR
Ritcher works
Ritcher Works
Tsentedrin
UNII-207ZZ9QZ49
α-phenyl-2-piperidineacetate methyl ester
α-phenyl-2-piperidineacetic acid methyl ester
|
|
2 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
3 |
|
Metformin |
Approved |
Phase 4 |
|
657-24-9 |
14219 4091 |
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
4 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
5 |
|
Celiprolol |
Approved, Investigational |
Phase 4 |
|
56980-93-9 |
|
Synonyms:
|
RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
|
|
6 |
|
Doxazosin |
Approved |
Phase 4 |
|
74191-85-8 |
3157 |
Synonyms:
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
1-(4-amino-6,7-Dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
Alfamedin
Aliud brand OF doxazosin mesylate
Almirall brand OF doxazosin mesylate
Alpharma brand OF doxazosin mesylate
Alter brand OF doxazosin mesylate
apo Doxazosin
apo-Doxazosin
Apogepha brand OF doxazosin mesylate
Apotex brand OF doxazosin mesylate
AstraZeneca brand OF doxazosin mesylate
Azupharma brand OF doxazosin mesylate
Betapharm brand OF doxazosin mesylate
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
Cantabria brand OF doxazosin mesylate
Cardular
Cardura
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
Carduran
Carduran neo
CHEBI:4708
CHEMBL707
ChemDiv2_005017
Ciclum brand OF doxazosin mesylate
CID3157
Cinfa brand OF doxazosin mesylate
combino Brand OF doxazosin mesylate
CPD000097306
CT Arzneimittel brand OF doxazosin mesylate
CT-Arzneimittel brand OF doxazosin mesylate
D07874
D9815_SIGMA
DB00590
Diblocin
Doxa puren
Doxacor
Doxagamma
Doxamax
Doxa-puren
Doxatensa
DoxaUro
Doxazomerck
doxazosin
Doxazosin
Doxazosin (INN)
Doxazosin [INN:BAN]
Doxazosin al
Doxazosin apogepha
Doxazosin azu
Doxazosin beta
Doxazosin findusfit
Doxazosin heumann
Doxazosin klast
Doxazosin mesilate
Doxazosin mesylate
Doxazosin monohydrochloride
Doxazosin ratiopharm
|
Doxazosin stada
Doxazosin von CT
Doxazosin wolff
Doxazosina
Doxazosina [Spanish]
Doxazosina alter
Doxazosina cinfa
Doxazosina combino pharm
Doxazosina geminis
Doxazosina normon
Doxazosina pharmagenus
Doxazosina ratiopharm
Doxazosina ur
Doxazosine
Doxazosine [French]
Doxazosin-ratiopharm
Doxazosinum
Doxazosinum [Latin]
Doxazosin-wolff
Esparma brand OF doxazosin mesylate
FindusFit brand OF doxazosin mesylate
Geminis brand OF doxazosin mesylate
Gen doxazosin
Gen-doxazosin
Genpharm brand OF doxazosin mesylate
Heumann brand OF doxazosin mesylate
Hexal brand OF doxazosin mesylate
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
Juta brand OF doxazosin mesylate
Jutalar
Kade brand OF doxazosin mesylate
L000738
Linden brand OF doxazosin mesylate
Lopac0_000474
LS-110228
Merck dura brand OF doxazosin mesylate
Mesylate, doxazosin
MolPort-001-684-491
Monohydrochloride, doxazosin
MTW Brand OF doxazosin mesylate
MTW Doxazosin
MTW-Doxazosin
NCGC00018158-06
NCGC00089775-02
neo, Carduran
Normon brand OF doxazosin mesylate
Normothen
novo Doxazosin
novo-Doxazosin
Novopharm brand OF doxazosin mesylate
Oprea1_259518
Pfizer brand OF doxazosin mesylate
Pharmagenus brand OF doxazosin mesylate
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
Progandol neo
Q Pharm brand OF doxazosin mesylate
Q-Pharm brand OF doxazosin mesylate
ratio Doxazosin
ratio-Doxazosin
Ratiopharm brand OF doxazosin mesylate
Ratiopharm, doxazosina
SAM002589981
Solvay brand OF doxazosin mesylate
SPBio_002796
Stadapharm brand OF doxazosin
TAD brand OF doxazosin mesylate
UK 33274
UK-33274
UNII-NW1291F1W8
Uriduct
Wolff brand OF doxazosin mesylate
Wörwag brand OF doxazosin mesylate
Zoxan
|
|
7 |
|
Phenoxybenzamine |
Approved |
Phase 4 |
|
59-96-1 |
4768 |
Synonyms:
102737-84-8
2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane
4-12-00-02204 (Beilstein Handbook Reference)
59-96-1
63-92-3 (hydrochloride)
688A
A 688
AB00053702
AC-13214
AC1L1IWT
Bensylyt
Bensylyt NEN
Bensylyte
Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine
Benzylyt
Bio2_000479
Bio2_000959
BPBio1_001000
BRN 2129697
BSPBio_000908
BSPBio_001278
BSPBio_002356
C07435
CCRIS 505
CHEBI:141434
CHEMBL753
CID4768
D08358
DB00925
Dibenylene
Dibenylin
Dibenyline
Dibenziran
Dibenzylene
Dibenzylin
Dibenzyline
Dibenzyran
DivK1c_000800
EINECS 200-446-8
Esparma brand OF phenoxybenzamine hydrochloride
Fenossibenzamina
Fenossibenzamina [DCIT]
Fenoxibenzamina
Fenoxibenzamina [INN-Spanish]
Goldshield brand OF phenoxybenzamine hydrochloride
HMS1362P19
HMS1792P19
HMS1990P19
HMS2089J09
HSDB 4005
Hydrochloride, phenoxybenzamine
IDI1_000800
IDI1_002234
|
KBio1_000800
KBio2_000618
KBio2_000858
KBio2_003186
KBio2_003426
KBio2_005754
KBio2_005994
KBio3_001095
KBio3_001096
KBioGR_000618
KBioGR_001158
KBioSS_000618
KBioSS_000858
L001197
Link brand OF phenoxybenzamine hydrochloride
Lopac0_000235
LS-43286
MolPort-001-785-595
N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine
N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine
N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine
N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
NCGC00015121-11
NCGC00089748-03
NCGC00089748-04
NCGC00089748-05
NCGC00089748-07
NINDS_000800
N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine
NSC 37448
phenoxybenzamine
Phenoxybenzamine
Phenoxybenzamine (INN)
Phenoxybenzamine [INN:BAN]
Phenoxybenzamine Hcl
Phenoxybenzamine hydrochloride
Phenoxybenzaminum
Phenoxybenzaminum [INN-Latin]
POB
POB HCl
Prestwick0_000944
Prestwick1_000944
Prestwick2_000944
Prestwick3_000944
SPBio_001829
SPBio_003067
Spectrum_000378
Spectrum2_001815
Spectrum4_000769
Spectrum5_001370
UNII-0TTZ664R7Z
Wellspring brand OF phenoxybenzamine hydrochloride
|
|
8 |
|
Pravastatin |
Approved |
Phase 4 |
|
81093-37-0 |
54687 |
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
apo Pravastatin
apo-Pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
BIDD:GT0773
BRD-K60511616-236-01-4
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
FT-0082682
Juste brand OF pravastatin sodium
KS-5015
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
LS-94713
Mevalothin
Mevalotin
Mevastatin
Mevinolin
|
nchembio.301-comp7
nchembio790-comp15
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
pravastatin
Pravastatin
Pravastatin (INN)
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin Sodium
Pravastatin sodium salt
Pravastatin Sodium Salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin tert-Octylamine Salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS 431
RMS-431
sankyo Brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
SQ-31,000
Squibb brand OF pravastatin sodium
UNII-KXO2KT9N0G
Vasten
|
|
9 |
|
Bevacizumab |
Approved, Investigational |
Phase 4 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
10 |
|
Curcumin |
Approved, Experimental, Investigational |
Phase 4 |
|
458-37-7 |
969516 |
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. 75300
C.I. natural yellow 3
CI natural yellow 3
Cucurmin
Curcuma
Curcumin I
Diferaloylmethane
Diferuloylmethane
e 100
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
|
Hydrastis
Kacha haldi
Merita earth
Natural yellow 3
Orange root
Safran d'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yellow, turmeric
yo-Kin
|
|
11 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
12 |
|
Vitamin D3 |
Approved, Nutraceutical |
Phase 4 |
|
67-97-0 |
5280795 6221 |
Synonyms:
()-Vitamin D3
(+)-vitamin D3
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
47763_SUPELCO
57651-82-8
67-97-0
7-DEHYDROCHOLESTEROL
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
ACTIVATED
Activated 7-dehydrocholesterol
Arachitol
Bio-0845
bmse000507
BPBio1_000460
BSPBio_000418
BSPBio_002408
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
Calciol
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
cholecalciferol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferols
Cholecalciferolum
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
|
CID7067440
CID7251172
CID7251174
CID9821465
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Dihydrocholesterol
DivK1c_006276
Duphafral D3 1000
Ebivit
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
FeraCol
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC375571
NSC-375571
Oleovitamin D3
Prestwick_63
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Provitamine
Provitina
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SpecPlus_000180
Spectrum_001163
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
SR-05000001559
SR-05000001559-3
ST057172
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
Vi-de-3-hydrosol
Vigorsan
VITAMIN D
Vitamin D 3
vitamin d-3
Vitamin D3
Vitamin D-3
Vitamin D3 emulsifiable
VITAMIN D3 POWDER
VITAMIN_D3
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
δ-D
|
|
13 |
|
Cilnidipine |
Investigational |
Phase 4 |
|
132203-70-4 |
5282138 |
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC1NQZJB
AC-270
Atelec
Atelec (TN)
Bio-0164
BRD-A07875874-001-01-6
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
cilnidipine
|
Cilnidipine
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
Siscard
STK623341
|
|
14 |
|
Enclomiphene |
Investigational |
Phase 4 |
|
15690-57-0 |
|
Synonyms:
|
trans-Clomifene
trans-Clomiphene
|
|
15 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
16 |
|
Central Nervous System Stimulants |
|
Phase 4 |
|
|
|
17 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
18 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
19 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
21 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
22 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
23 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
24 |
|
Citrate |
|
Phase 4 |
|
|
|
25 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
26 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
27 |
|
Estrogen Receptor Antagonists |
|
Phase 4 |
|
|
|
28 |
|
Estrogen Antagonists |
|
Phase 4 |
|
|
|
29 |
|
Estrogens |
|
Phase 4 |
|
|
|
30 |
|
Estrogen Receptor Modulators |
|
Phase 4 |
|
|
|
31 |
|
Clomiphene |
|
Phase 4 |
|
|
|
32 |
|
Zuclomiphene |
|
Phase 4 |
|
|
|
33 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
34 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
35 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
36 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
37 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
38 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
39 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
40 |
|
Angiogenesis Inhibitors |
|
Phase 4 |
|
|
|
41 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
42 |
|
Analgesics |
|
Phase 4 |
|
|
|
43 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
44 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
45 |
|
Somatostatin |
Approved, Investigational |
Phase 2, Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 |
Synonyms:
Growth hormone-inhibiting hormone (ghih)
Somatostatin
Somatostatina
Somatostatine
Somatostatinum
|
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
Synthetic growth hormone release-inhibiting hormone
Synthetic somatostatin-14
|
|
46 |
|
lanreotide |
Approved |
Phase 2, Phase 3 |
|
108736-35-2 |
|
Synonyms:
|
47 |
|
Spironolactone |
Approved |
Phase 3 |
|
52-01-7, 1952-01-7 |
5833 |
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
496916-40-6
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
52-01-7
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
AB00513806
Abbolactone
AC1L1L8Q
AC-4214
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone a
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alphapharm Brand of Spironolactone
Alpharma brand OF spironolactone
Alpharma Brand of Spironolactone
Alter brand OF spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Ashbourne Brand of Spironolactone
Azupharma brand OF spironolactone
Azupharma Brand of Spironolactone
betapharm Brand of Spironolactone
Betapharm brand OF spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
Cardel brand OF spironolactone
Cardel Brand of Spironolactone
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
ct Arzneimittel Brand of Spironolactone
CT Arzneimittel brand OF spironolactone
ct-Arzneimittel Brand of Spironolactone
CT-Arzneimittel brand OF spironolactone
D00443
D013148
DB00421
Deverol
dexo Brand OF spironolactone
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona Alter
Espironolactona mundogen
Espironolactona Mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
Hormosan brand OF spironolactone
Hormosan Brand of Spironolactone
HSDB 3184
I06-1970
Jenapharm brand OF spironolactone
Jenapharm Brand of Spironolactone
Jenaspiron
Lacalmin
Lacdene
Laractone
LS-118614
LT00772287
Mayoly-spindler brand OF spironolactone
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura brand OF spironolactone
Merck dura Brand of Spironolactone
MLS001074672
MLS001333253
MLS001333254
|
MLS002153245
MLS002207058
Mundogen brand OF spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
NCGC00164397-02
Nefurofan
novo Spiroton
Novo Spiroton
Novopharm brand OF spironolactone
Novopharm Brand of Spironolactone
novo-Spiroton
NovoSpiroton
Novo-Spiroton
NSC 150399
NSC150399
Osyrol
Pfizer brand OF spironolactone
Pfizer Brand of Spironolactone
Pharmafrid brand OF spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche brand OF spironolactone
Roche Brand of Spironolactone
S0260
S3378_SIGMA
Sagisal
SAM002264648
SC 9420
SC9420
SC-9420
Searle brand OF spironolactone
Searle Brand of Spironolactone
Sincomen
SMR000471892
SNL
SPBio_002115
Spiractin
Spiresis
Spiretic
Spiridon
spiro L.U.T.
Spiro L.U.T.
spiro von ct
spiro Von CT
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
spirono Isis
Spirono Isis
Spironocompren
spirono-Isis
Spirono-Isis
spironolactone
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
spironolattone
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Spiro-Tablinen
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
von ct, spiro
Von CT, spiro
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Wörwag brand OF spironolactone
Xenalon
ZINC03861599
|
|
48 |
|
Octreotide |
Approved, Investigational |
Phase 2, Phase 3 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
Compound 201 995
Compound 201995
Compound 201-995
D00442
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DRG-0115
HMS2090C09
HS-2020
L000453
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
|
Longastatin
LS-177735
LS-187135
NCGC00181796-01
nchembio.184-comp3
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide acetate salt
Octreotide Acetate Salt
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
Sandostatin
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SM 201-995
SMS 201-995
SMS-201-995
UNII-RWM8CCW8GP
zacycloicosane-4-carboxamide acetate
|
|
49 |
|
carbamide peroxide |
Approved |
Phase 2, Phase 3 |
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
50 |
|
Hydrochlorothiazide |
Approved, Vet_approved |
Phase 3 |
|
58-93-5 |
3639 |
Synonyms:
125727-50-6
3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi
3,4-Dihydrochlorothiazide
58-93-5
6-Chloro-7-sulfamoyl-3, 4-dihy
8049-49-8
AB00052012
AC-11072
AC1L1GDT
AC1Q55FM
Acesistem
Acuilix
Acuretic
adiazine-1,1-dioxide
AF-614/30832002
AKOS000121373
Aldactazide
Aldactazide 25/25
Aldazida
Aldectazide 50/50
Aldoril
Ambap58-93-5
Apo-Hydro
Apresazide
Aquarills
Aquarius
Aquazide H
Aquazide-H
ARONIS24316
BAS 00371709
BIDD:GT0153
Bio-0714
BPBio1_000019
BRD-K13078532-001-05-2
Bremil
Briazide
BRN 0625101
BSPBio_000017
BSPBio_002132
C7H8ClN3O4S2
Caplaril
Capozide
Carozide
CAS-58-93-5
Catiazida
CCRIS 2082
CHEMBL435
Chlorizide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Chlothia
CID3639
Cidrex
Clorana
component of Aldactazide
component of Aldoril
Component of Butizide Prestabs
component of Caplaril
component of Cyclex
component of Dyazide
component of Esimil
Concor Plus
Condiuren
CPD000035778
D00340
D006852
DB00999
Diaqua
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
diclot ride
Diclotride
Dicyclotride
Didral
Dihydran
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Disothiazid
Diu 25 Vigt
Diu-melusin
Diu-Melusin
Diuril
Diurogen
DivK1c_000289
Dixidrasi
Drenol
dro-2H-1,2,4-benzothiadiazine 1,1-dioxide
Dyazide
EINECS 200-403-3
Esidrex
Esidrix
Esidrix (TN)
Esimil
Esoidrina
EU-0100614
Fluvin
FT-0082750
H 4759
H1274
H2910_SIAL
H4759_SIAL
HCT
HCT-Isis
HCTZ
HCZ
Hidril
Hidrochlortiazid
Hidroclorotiazida
Hidroclorotiazida [INN-Spanish]
Hidro-Niagrin
Hidroronol
Hidrosaluretil
Hidrotiazida
HMS1568A19
HMS1920D19
HMS2091L05
HMS500O11
HMS553N04
HSDB 3096
Hyclosid
Hydrex-semi
Hydril
Hydro Par
hydro-Aquil
Hydro-Aquil
Hydro-chlor
Hydrochlorat
hydrochloro Thiazide
Hydrochlorot
Hydrochlorothiazid
hydrochlorothiazide
Hydrochlorothiazide
Hydrochlorothiazide (JP15/USP/INN)
|
Hydrochlorothiazide [INN:BAN:JAN]
Hydrochlorothiazide intensol
Hydrochlorothiazide Intensol
Hydrochlorothiazidum
Hydrochlorothiazidum [INN-Latin]
Hydrochlorthiazide
Hydrochlorthiazidum
Hydrocot
hydro-D
Hydro-D
Hydrodiuretic
hydro-Diuril
Hydrodiuril
Hydro-Diuril
HydroDIURIL
Hydropres
Hydrosaluric
Hydro-Saluric
Hydro-T
Hydrothide
Hydrozide
Hydrozide Injection, Veterinary
Hypothiazid
Hypothiazide
Hytrid
Hyzaar
I09-0531
IDI1_000289
Idroclorotiazide
Idroclorotiazide [DCIT]
Idrotiazide
Inderide
Inderide 80/25
Indroclor
Ivaugan
Jen-diril
Jen-Diril
KBio1_000289
KBio2_001357
KBio2_003925
KBio2_006493
KBio3_001352
KBioGR_000351
KBioSS_001357
Lopac0_000614
Lopac-H-4759
Lopressor HCT
Lotensin Hct
Lotensin HCT
LS-243
Manuril
Maschitt
Maxzide
Maybridge Compound 10
Maybridge1_004336
Mazide 25 mg
Medozide
Megadiuril
Microzide
Microzide (TN)
Mictrin
Mikorten
MLS000069619
Modurcen
Moduretic
MolPort-000-144-465
Natrinax
NCGC00015508-01
NCGC00015508-02
NCGC00015508-03
NCGC00015508-07
NCGC00015508-12
NCGC00021906-03
NCGC00021906-04
NCGC00021906-05
NCGC00021906-06
NCGC00021906-07
NCGC00021906-08
NCI60_004317
NCI-C55925
Nefrix
Nefrol
neo-Codema
Neo-codema
Neo-Codema
Neoflumen
Neo-Flumen
Neo-Minzil
Newtolide
NINDS_000289
Novodiurex
NSC 53477
NSC53477
Oprea1_357174
Oretic
Pantemon
Panurin
panurin dichloride
Prestwick_263
Prestwick0_000009
Prestwick1_000009
Prestwick2_000009
Prestwick3_000009
Prinzide
Raunova Plus
ro-Hydrazide
Ro-hydrazide
Ro-Hydrazide
Roxane
S1708_Selleck
Saldiuril
SAM002554901
Sectrazide
Selozide
Ser-ap-es
Servithiazid
SMR000035778
SPBio_001259
SPBio_001938
Spectrum_000877
SPECTRUM1500335
Spectrum2_001040
Spectrum3_000456
Spectrum4_000006
Spectrum5_000824
Spironazide
STK315354
Su 5879
Tandiur
Thiaretic
Thiuretic
Thlaretic
Timolide
Unazid
UNII-0J48LPH2TH
Unipres
Urodiazin
Urozide
Vaseretic
Vetidrex
WLN: T66 BSWM EM DHJ HG ISZW
Ziac
Zide
ZINC00896569
|
|
Interventional clinical trials:
(show top 50)
(show all 418)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients |
Unknown status |
NCT00541853 |
Phase 4 |
Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents |
2 |
Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo |
Completed |
NCT00169611 |
Phase 4 |
methylphenidate |
3 |
A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Completed |
NCT00414440 |
Phase 4 |
Placebo;Everolimus |
4 |
Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome |
Completed |
NCT00190411 |
Phase 4 |
celiprolol;Control |
5 |
Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial: PROTECT Continued Access Post Marketing Surveillance Trial |
Completed |
NCT00846846 |
Phase 4 |
|
6 |
Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant Polycystic Ovary Syndrome Women |
Completed |
NCT04010942 |
Phase 4 |
Vit D;Metformin;Clomiphene |
7 |
Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment |
Completed |
NCT01379898 |
Phase 4 |
Phenoxybenzamine;Doxazosin |
8 |
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease |
Recruiting |
NCT03949894 |
Phase 4 |
Tolvaptan |
9 |
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease |
Recruiting |
NCT03596957 |
Phase 4 |
Tolvaptan |
10 |
Statin Therapy in Patients With Early Stage ADPKD |
Recruiting |
NCT03273413 |
Phase 4 |
Pravastatin;Placebo |
11 |
Intranasal Bevacizumab for HHT-Related Epistaxis |
Recruiting |
NCT02389959 |
Phase 4 |
Bevacizumab;Placebo (Saline) |
12 |
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD |
Active, not recruiting |
NCT02494141 |
Phase 4 |
Curcumin |
13 |
Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Unknown status |
NCT02115659 |
Phase 3 |
Triptolide-Containing Formulation;Placebo |
14 |
An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver |
Unknown status |
NCT01680250 |
Phase 2, Phase 3 |
Sirolimus |
15 |
The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD |
Unknown status |
NCT01616927 |
Phase 3 |
Lanreotide |
16 |
First Clinical Study of Erbium-YAG Laser Vaporisation of Cutaneous Neurofibromas |
Unknown status |
NCT00921037 |
Phase 2, Phase 3 |
|
17 |
Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft |
Unknown status |
NCT02878694 |
Phase 2, Phase 3 |
|
18 |
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT00456365 |
Phase 3 |
pravastatin;Placebo |
19 |
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] |
Completed |
NCT01022424 |
Phase 3 |
OPC-41061 |
20 |
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] |
Completed |
NCT01280721 |
Phase 3 |
tolvaptan |
21 |
Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Completed |
NCT01214421 |
Phase 3 |
Tolvaptan |
22 |
Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02119052 |
Phase 2, Phase 3 |
octeotride;placebo |
23 |
An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02134899 |
Phase 3 |
Everolimus;Calcineurin inhibitors maintenance |
24 |
Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers |
Completed |
NCT00565097 |
Phase 2, Phase 3 |
Placebo;Lanreotide |
25 |
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02251275 |
Phase 3 |
Tolvaptan |
26 |
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT00428948 |
Phase 3 |
Tolvaptan;Placebo |
27 |
Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study. |
Completed |
NCT00346918 |
Phase 3 |
Sirolimus |
28 |
EFFECT OF SOMATOSTTIN ON EARLY DIASTOLIC LEFT VENTRICULAR FUNCTION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A MATCHED-COHORT, SPECKLE-TRACKING ECHOCARDIOGRAPHIC STUDY |
Completed |
NCT02119013 |
Phase 2, Phase 3 |
Octeotride;Placebo |
29 |
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02160145 |
Phase 3 |
Tolvaptan (OPC-41061);Placebo |
30 |
Lanreotide In Polycystic Kidney Disease Study |
Completed |
NCT02127437 |
Phase 3 |
Lanreotide;saline |
31 |
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney |
Completed |
NCT01853553 |
Phase 3 |
Spironolactone;Sugar pill |
32 |
An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT01576367 |
Phase 3 |
|
33 |
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD |
Completed |
NCT03803124 |
Phase 3 |
Tolvaptan;Placebo |
34 |
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT01302860 |
Phase 3 |
ACZ885 |
35 |
Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD |
Completed |
NCT02225860 |
Phase 2, Phase 3 |
|
36 |
Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease |
Completed |
NCT00426153 |
Phase 2, Phase 3 |
Octreotide;Placebo |
37 |
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY |
Completed |
NCT01377246 |
Phase 3 |
Octreotide-LAR |
38 |
An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan |
Completed |
NCT00991146 |
Phase 3 |
canakinumab |
39 |
An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease |
Completed |
NCT00685373 |
Phase 3 |
Canakinumab (ACZ885) |
40 |
A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome |
Completed |
NCT00465985 |
Phase 3 |
ACZ885;Placebo |
41 |
Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study |
Completed |
NCT00309283 |
Phase 3 |
Long-acting somatostatin |
42 |
A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex |
Completed |
NCT02635789 |
Phase 3 |
NPC-12G gel;Placebo gel |
43 |
A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex |
Completed |
NCT02634931 |
Phase 3 |
NPC-12G gel |
44 |
Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. |
Completed |
NCT00632645 |
Phase 3 |
Olanzapine;Xenazine;Tiapridal |
45 |
Pharmacokinetics Berinert P Study of Subcutaneous Versus Intravenous Administration in Subjects With Moderate Hereditary Angioedema - The Passion Study |
Completed |
NCT00748202 |
Phase 3 |
C1-Esterase Inhibitor |
46 |
The Effect of Diflunisal on Familial Amyloidosis |
Completed |
NCT00294671 |
Phase 2, Phase 3 |
diflunisal |
47 |
HALT Progression of Polycystic Kidney Disease Study B |
Completed |
NCT01885559 |
Phase 3 |
Lisinopril;Telmisartan;Placebo |
48 |
Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial. |
Completed |
NCT01104649 |
Phase 2, Phase 3 |
riluzole;Placebo comparator |
49 |
Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 |
Completed |
NCT01096082 |
Phase 2, Phase 3 |
Lithium Carbonate;Placebo |
50 |
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease |
Completed |
NCT00706849 |
Phase 3 |
mipomersen sodium;placebo |
Search
NIH Clinical Center
for Contractures, Pterygia, and Spondylocarpotarsal Fusion Syndrome 1a
|